Investigating how compounds from mangosteen can help degrade androgen receptors in prostate cancer
Defining the role of isoprenylated xanthones from the mangosteen for enhancing degradation of full length and variant forms of androgen receptor in prostate cancer
['FUNDING_R37'] · UNIVERSITY OF ILLINOIS AT CHICAGO · NIH-11086058
This study is looking at how a natural compound from mangosteen, called α-mangostin, might help break down certain proteins that can make prostate cancer harder to treat, with the hope of finding better treatment options for patients.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ILLINOIS AT CHICAGO (nih funded) |
| Locations | 1 site (Chicago, UNITED STATES) |
| Trial ID | NIH-11086058 on ClinicalTrials.gov |
What this research studies
This research focuses on the potential of α-mangostin, a compound derived from mangosteen, to enhance the degradation of androgen receptors, which are critical in the progression of prostate cancer. The study examines how this compound interacts with various androgen receptor variants that are associated with treatment resistance. By using advanced cell models, researchers aim to understand the mechanisms by which α-mangostin can promote the breakdown of these receptors, potentially leading to more effective treatments for patients with prostate cancer. The research also explores the role of a specific protein, BiP, in regulating this degradation process.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with prostate cancer, particularly those exhibiting resistance to current androgen-targeting therapies.
Not a fit: Patients with early-stage prostate cancer who are not yet experiencing resistance to androgen therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that improve treatment outcomes for patients with androgen-resistant prostate cancer.
How similar studies have performed: While the specific approach of using α-mangostin is novel, there have been successful studies exploring the degradation of androgen receptors in prostate cancer using other small molecules.
Where this research is happening
Chicago, UNITED STATES
- UNIVERSITY OF ILLINOIS AT CHICAGO — Chicago, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JOHNSON, JEREMY JAMES — UNIVERSITY OF ILLINOIS AT CHICAGO
- Study coordinator: JOHNSON, JEREMY JAMES
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: androgen independent prostate cancer, androgen indifferent prostate cancer, androgen insensitive prostate cancer, androgen resistance in prostate cancer, androgen resistant prostate cancer